Moderna-Merck Melanoma Vaccine Breakthrough Sends Shares Skyrocketing

Moderna's partnership with Merck has yielded positive results in a late-stage trial for their melanoma vaccine. The therapy, which combines Moderna's personalized mRNA cancer treatment with Merck's Keytruda, reduced the risk of melanoma recurrence and spread compared to using Keytruda alone. This significant improvement sent Moderna's shares soaring nearly 90% and Merck's up by 10%. Analysts see this breakthrough as a major confidence booster for investors, but warn that full trial data has yet to be released.

Dr. Ryan Sullivan, Director of Cutaneous Medical Oncology at Mass General Brigham Cancer Institute, hailed the development as 'a big deal' for the field, stating that if the trial had been negative, mRNA-based cancer therapies and vaccinations may never have recovered. Others, like Peter Andersen of Andersen Capital Management, noted that this news will draw more investors into pharmaceuticals, but emphasized it's a case-by-case situation.

Trung Huynh of RBC Capital Markets pointed out that the strength of the underlying data must have been compelling to trigger significance at the interim analysis. Meanwhile, Andrew Tsai of Jefferies predicted that the vaccine for melanoma could enter the market in 2027 and estimated peak sales potential to be 'multi-billion' if the partners market the product outside the U.S.

Lale Akeron of Etoro cautioned that retail investors should keep expectations measured, as manufacturing personalized vaccines at scale may be expensive and complex. Art Hogan, Chief Market Strategist at B Riley Wealth in NY, saw this development as 'great early-stage news' for Moderna, which has been lagging since the post-pandemic timeframe.